{"denoms":[{"counts":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"252"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"532"}],"units":"Participants"}],"groups":[{"description":"Participants with surgically unsalvageable disease (eg, sacral, spinal GCTB, or multiple lesions including pulmonary metastases) were enrolled into cohort 1 and received denosumab 120 mg SC once Q4W, starting on study day 1, plus loading doses of 120 mg SC on days 8 and 15 in the first month of treatment.","id":"BG000","title":"Cohort 1 (Denosumab 120 mg Q4W)"},{"description":"Participants with surgically salvageable disease whose planned initial on-study surgery was associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy) were enrolled into cohort 2 and received denosumab 120 mg SC Q4W, starting on study day 1, plus loading doses of 120 mg SC on days 8 and 15 in the first month of treatment.","id":"BG001","title":"Cohort 2 (Denosumab 120 mg Q4W)"},{"description":"Participants who participated in study 20040215 and were eligible to enroll in the current study (20062004) for continuation of treatment were enrolled into cohort 3 and received denosumab 120 mg SC Q4W, starting on study day 1. Participants in cohort 3 did not receive loading doses of denosumab on days 8 and 15 in the first month of treatment.","id":"BG002","title":"Cohort 3 (Denosumab 120 mg Q4W)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"28"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"231"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"481"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"23"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.6","value":"36.4"},{"groupId":"BG001","spread":"13.5","value":"35.1"},{"groupId":"BG002","spread":"14.9","value":"36.1"},{"groupId":"BG003","spread":"14.1","value":"35.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"301"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"231"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"221"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"440"}]}],"title":"White or Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"30"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"27"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"25"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"9"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"167"}]}],"title":"Primary resectable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"95"}]}],"title":"Primary unresectable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"85"}]}],"title":"Recurrent resectable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"185"}]}],"title":"Recurrent unresectable"}],"paramType":"NUMBER","title":"GCTB Disease Type","unitOfMeasure":"Participants"}],"populationDescription":"The overall baseline population consisted of the 532 participants enrolled into the treatment phase of the study."}